Skip to main content

Advertisement

SpringerLink
Log in

Treatment strategies for chemotherapy-induced peripheral neuropathy: potential role of exercise

  • Review
  • Published:
Oncology Reviews

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common, dose-limiting effect of cancer therapy that often has negative implications on a patient’s quality of life. The pain associated with CIPN has long been recognized as one of the most difficult types of pain to treat. Historically, much effort has been made to explore pharmacological therapies aimed at reducing symptoms of CIPN. While many of these agents provide a modest relief in the symptoms of peripheral neuropathy, many have been shown to have additional negative side effects for cancer patients. Therefore, the authors suggest exercise rehabilitation as one lifestyle modification that may positively impact the lives of patients with CIPN. To our knowledge, there are currently no published clinical trials examining the role of exercise in preserving neurological function following chemotherapy. However, investigations using low-to-moderate intensity exercise as an intervention in patients with diabetic peripheral neuropathy and hereditary motor and sensory neuropathies have produced promising results. Given that cancer patients appear to tolerate exercise, it seems plausible that exercise rehabilitation could be used as an effective strategy to minimize CIPN-induced detriments to quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. American Cancer Society (2009) Cancer facts & figures 2009. Author, Atlanta, GA

  2. National Heart, Lung, and Blood Institute (2008) NHLBI fact book, fiscal year 2007. Author, Bethesda, MD

  3. National Cancer Institute (2009) Office of Cancer Survivorship. http://dccps.nci.nih.gov/ocs/researcher_factsheet.pdf. Retrieved 5 December 2009

  4. Ganz PA (2007) Cancer survivorship: today and tomorrow. Springer, New York, pp 1–7

    Google Scholar 

  5. Lind J (1992) Tumor cell growth and cell kinetics. Semin Oncol Nurs 8(1):3–9

    CAS  PubMed  Google Scholar 

  6. Rieger PT (2006) Cancer biology and implications for treatment. Clin J Oncol Nurs 10(4):457–460

    PubMed  Google Scholar 

  7. Honea N, Brant J, Beck SL (2007) Treatment-related symptom clusters. Sem Oncol Nurs 23(2):142–151

    Google Scholar 

  8. Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249:9–17

    CAS  PubMed  Google Scholar 

  9. Antonine JC, Camdessanche JP (2007) Peripheral nervous system involvement in patients with cancer. Lancet Neurol 6:75–86

    Google Scholar 

  10. Kaley TJ, DeAngelis LM (2009) Therapy of chemotherapy-induced peripheral neuropathy. Br J Haematol 145:3–14

    CAS  PubMed  Google Scholar 

  11. Stubblefield MD, Burstein HJ, Burton AW, Custodio CM, Deng GE, Ho M et al. (2009) NCCN task force report: management of neuropathy in cancer. J NCCN 7:S-1-28

    Google Scholar 

  12. Woolf CJ (2004) Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 140:441–445

    PubMed  Google Scholar 

  13. Horowitz SH (2007) The diagnostic workup of patients with neuropathic pain. Med Clin N Am 91:21–30

    PubMed  Google Scholar 

  14. National Health & Medical Research Council (1999) Acute pain management: scientific evidence. Commonwealth of Australia, Australia

  15. Verstappen CP, Heimans JJ, Hoekman K, Postma TJ (2003) Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs 63(15):1549–1563

    CAS  PubMed  Google Scholar 

  16. Visovsky C (2003) Chemotherapy-induced peripheral neuropathy. Cancer Investig 21(3):439–451

    Google Scholar 

  17. Wolf CJ, Mannion RJ (1999) Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 353:1959–1964

    Google Scholar 

  18. Reyes-Gibby CC, Marrow PK, Buzdar A, Shete S (2009) Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel. J Pain 10:1146–1150

    CAS  PubMed  Google Scholar 

  19. Tulub AA, Stefanov VE (2001) Cisplatin stops tubulin assembly into microtubules. A new insight into the mechanisms of antitumor activity of platinum complexes. Int J Biol Macromol 28:191–198

    CAS  PubMed  Google Scholar 

  20. Benoit E, Brienza S, Dubois JM (2006) Oxaliplatin, an anticancer agent that affects both Na+ and K+ channels in frog peripheral myelinated axons. Gen Physiol Biophys 25:263–276

    CAS  PubMed  Google Scholar 

  21. Scadding JW, Kiltzenburg M (2006) Painful peripheral neuropathies. In: McMahon SB, Koltzenburg M (eds) Wall and Melzacks, textbook of pain, 5th edn. Elsevier Churchill Livingstone, Philadelphia, PA, pp 973–999

    Google Scholar 

  22. Jensen TS, Baron R (2003) Translation of symptoms and signs into mechanisms of neuropathic pain. Pain 102:13–18

    Google Scholar 

  23. Ahmad M, Goucke CR (2002) Management strategies for the treatment of neuropathic pain in the elderly. Drug Aging 19:929–945

    CAS  Google Scholar 

  24. Bakitas MA, Smith E, Cohen J, Fadul C (2004) Measurement issues in chemotherapy-induced peripheral neuropathy. In: Paper presented at the international conference on the mechanisms and treatment of neuropathic pain, Bermuda, November 4–6, 2004

  25. Grothey A (2007) Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 30(suppl 15):5–13

    Google Scholar 

  26. Tolle T, Zu Z, Sadosky AB (2006) Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complications 20:26–33

    PubMed  Google Scholar 

  27. Zelman D, Core M, Dukes E, Tai K, Brandenburg N (2005) Validation of a modified version of the brief pain inventory for painful diabetic peripheral neuropathy. J Pain Symptom Manage 29:401–410

    PubMed  Google Scholar 

  28. Jensen MP, Hoffman AJ, Cardenas DD (2005) Chronic pain in individuals with spinal cord injury: a survey and longitudinal study. Spinal Cord 43:704–712

    CAS  PubMed  Google Scholar 

  29. Bergbom-Engberg I, Grondahl G, Thibom K (1995) Patients’ experiences of herpes zoster and postherpetic neuralgia. J Adv Nurs 21:427–433

    Google Scholar 

  30. Galer B, Gianas A, Jensen M (2000) Painful diabetic polyneuropathy: epidemiology, pain, description, and quality of life. Diabetes Res Clin Pract 47:123–128

    CAS  PubMed  Google Scholar 

  31. Tasmuth T, von Smitten K, Hietanen P et al (1995) Pain and other symptoms after different treatment modalities of breast cancer. Ann Oncol 6:453–459

    CAS  PubMed  Google Scholar 

  32. Flier J, Van Muiswinkel FL, Jongenen CA et al (2002) The neuroprotective antioxidant alpha-lipoic acid induces detoxication enzymes in cultured astroglail cells. Free Radic Res 36:695–699

    CAS  PubMed  Google Scholar 

  33. Bianchi G, Vitali G, Caraceni A et al (2005) Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced peripheral neuropathy to oral acetyl-L-carnitine. Eur J Cancer 41:1746–1750

    CAS  PubMed  Google Scholar 

  34. Tankova T, Cherninkova S, Koev D (2005) Treatment for diabetic mononeuropathy with alpha-lipoic acid. Int J Clin Pract 59:645–650

    CAS  PubMed  Google Scholar 

  35. Eckel F, Schmelz R, Adelsberger H et al (2002) Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study. Dtsch Med Wochenchr 127:78–82

    CAS  Google Scholar 

  36. Sindrup S, Jensen T (1999) Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 83:389–400

    CAS  PubMed  Google Scholar 

  37. Goodman LS, Limbird LE, Milinoff PB et al (eds) (1996) Goodman and Gilman’s: the pharmacological basis of therapeutics, 9th edn. McGraw-Hill Professional, New York

    Google Scholar 

  38. Jensen TS (2002) Anticonvulsants in neuropathic pain. Eur J Pain 6(Suppl A):61–68

    CAS  PubMed  Google Scholar 

  39. Backonja M, Beydoun A, Edwards KR et al (1978) Gabapentin for the symptomatic treatment of painful neuropathy. J Assoc Physicians India 26(5):403–406

    Google Scholar 

  40. Rao RD, Michalak JD, Sloan JA et al (2007) Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy. Cancer 110:2110–2118

    CAS  PubMed  Google Scholar 

  41. Gatti G, Bonomi I, Jannuzzi G et al (2000) The new antiepileptic drugs: pharmacological and clinical aspects. Curr Pharm Des 6:839–860

    CAS  PubMed  Google Scholar 

  42. Gwag BJ, Sessler FM, Robine V et al (1997) Endogenous glutamate levels regulate nerve growth factor mRNA expression in the rat denate gyrus. Mol Cells 7:425–430

    CAS  PubMed  Google Scholar 

  43. De Santis S, Pace A, Bove L et al (2000) Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin Cancer Res 6:90–95

    PubMed  Google Scholar 

  44. Bailey HH, Gipp JJ, Ripple M, Wilding G, Mulcahy RT (1992) Increase in gamma-glutamylcysteine synthetase activity and steady-state messenger RNA levels in melphalan-resistant DU-145 human prostate carcinoma cells expressing elevated glutathione levels. Cancer Res 52:5115–5118

    CAS  PubMed  Google Scholar 

  45. Britten RA, Green JA, Warenius HM (1992) Cellular glutathione (GSH) and glutathione S-transferase (GST) activity in human ovarian tumor biopsies following exposure to alkylating agents. Int J Radiat Oncol Biol Phys 24:527–531

    CAS  PubMed  Google Scholar 

  46. Joncourt F, Oberli-Schrammli AE, Stadler M et al (1995) Patterns of drug resistance parameters in adult leukemia. Leuk Lymph 17:101–109

    CAS  Google Scholar 

  47. Perry RR, Mazetta JA, Levin M, Barranco SC (1993) Glutathione levels and variability in breast tumors and normal tissue. Cancer 72:783–787

    CAS  PubMed  Google Scholar 

  48. Redmond SM, Joncourt F, Buser K et al (1991) Assessment of P-glycoprotein, glutathione-based detoxidying enzymens and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res 51:2092–2097

    CAS  PubMed  Google Scholar 

  49. Mulder TP, Manni JJ, Roelofs HM, Peters WH, Wiersma A (1995) Glutathione S-transferases and glutathione in human head and neck cancer. Carcinogenesis 16:619–624

    CAS  PubMed  Google Scholar 

  50. Cook JA, Pass HI, Iype SN et al (1991) Cellular glutathione and thiol measurements from surgically resected human lung tumor and normal lung tissue. Cancer Res 51:4287–4294

    CAS  PubMed  Google Scholar 

  51. Suzuki T, Nishio K, Tanabe S (2001) The MRP family and anticancer drug metabolism. Curr Drug Metab 2:367–377

    CAS  PubMed  Google Scholar 

  52. Kawai H, Kiura K, Tabata M et al (2002) Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy. Lung Cancer 35:305–314

    PubMed  Google Scholar 

  53. Smyth JF, Bowman A, Parren T et al (1997) Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomized trial. Ann Oncol 8:569–573

    CAS  PubMed  Google Scholar 

  54. Cascinu S, Cordella L, Del Ferro E et al (1995) Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 13:26–32

    CAS  PubMed  Google Scholar 

  55. Eisenberg E, Lurie Y, Braker C et al (2001) Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 57:505–509

    CAS  PubMed  Google Scholar 

  56. Canavero S, Bonicalz V (1996) Lamotrigine control of central pain. Pain 68:179–181

    CAS  PubMed  Google Scholar 

  57. Renno SI, Rao RD, Sloan J et al (2006) The efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase III randomized, double blind, placebo-controlled NCCTG trial, N01C3. J Clin Oncol 24(185):8530

    Google Scholar 

  58. Saudek CD, Werns S, Reidenberg MM (1977) Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clin Pharmacol Ther 22(2):196–199

    CAS  PubMed  Google Scholar 

  59. Tremont-Lukats IW, Megeff C, Backonja MM (2000) Anticonvulsants for neuropathic pain syndromes: Mechanisms of action and place in therapy. Drugs 60:1029–1052

    CAS  PubMed  Google Scholar 

  60. Wilson RH, Lehky T, Thomas RR et al (2002) Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20:1767–1774

    CAS  PubMed  Google Scholar 

  61. Traber MG (2006) Vitamin E. In: Shils ME, Shike M, Ross AC, Caballero B, Cousins R (eds) Modern nutrition in health and disease, 10th edn. Lippincott Williams & Wilkins, Baltimore, pp 396–411

    Google Scholar 

  62. Argyriou AA, Chroni E, Koutras A et al (2005) Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 64:26–31

    CAS  PubMed  Google Scholar 

  63. Pace A, Savarese A, Picardo M et al (2003) Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 21:927–931

    CAS  PubMed  Google Scholar 

  64. Jacobs EJ, Henion AK, Briggs PJ et al (2002) Vitamin C and vitamin E supplement use and bladder cancer mortality in a large cohort of US men and women. Am J Epidemiol 156:1002–1010

    PubMed  Google Scholar 

  65. Moore DH, Donnelly J, McGuire WP et al (2003) Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neuropathy: a phase II study of the Gynecologic Oncology Group. J Clin Oncol 21:4207–4213

    CAS  PubMed  Google Scholar 

  66. Nelson DF, Gillespie BW, Diener MD et al (1984) Is misonidazole neurotoxicity altered by the use of phenytoin and/or dexamethasone in ROTG 79-18 and RTOG 79-16? Int J Radiat Oncol Biol Phys 10:1731–1734

    CAS  PubMed  Google Scholar 

  67. Bergouignan FX, Vital C, Henry P et al (1988) Disulfiram neuropathy. J Neurol 235:382–383

    CAS  PubMed  Google Scholar 

  68. Lehky TJ, Leonard GD, Wilson RH et al (2004) Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29:387–392

    CAS  PubMed  Google Scholar 

  69. Davis ID, Kiers L, MacGregor L et al (2005) A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res 11:1890–1898

    CAS  PubMed  Google Scholar 

  70. Hamers FP, van der Hoop RG, Steerenburg PA et al (1991) Putative neurotrophic factors in the protection of cisplatin-induced peripheral neuropathy in rats. Toxicol Appl Pharmacol 111:514–522

    CAS  PubMed  Google Scholar 

  71. Roberts JA, Jenison EL, Kim K et al (1997) A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol 67:172–177

    CAS  PubMed  Google Scholar 

  72. Markes M, Brockow T, Resch KL (2008) Exercise for women receiving adjuvant therapy for breast cancer (Review). The Cochrane Collection, Published by Wiley Ltd in The Cochrane Library, Issue 4

  73. Irwin ML, Crumley D, McTiernan A, Bernstein L, Baumgartner R, Gilliland FD, Kriska A, Ballard-Barbash R (2003) Physical activity levels before and after a diagnosis of breast carcinoma: the Healthy Eating, Activity, and Lifestyle (HEAL) study. Cancer 97(7):1746–1757

    PubMed  Google Scholar 

  74. Herrero F, San Juan AF, Fleck SJ, Balmer J, Perez M, Canete S, Earnest CP, Foster C, Lucia A (2005) Combined aerobic and resistance training in breast cancer survivors: a randomized, controlled pilot trial. Int J Sports Med 26(4):294–302

    PubMed  Google Scholar 

  75. Aitken DR, James AG (1997) Seromas and physiotherapy after mastectomy. Ann Surg Oncol 4(4):293–297

    Google Scholar 

  76. Schneider CM, Dennehy CA, Roozeboom M, Carter SD (2002) A model program: exercise intervention for cancer rehabilitation. Integr Cancer Ther 1:76–82

    CAS  PubMed  Google Scholar 

  77. Schneider CM, Hsieh CC, Sprod LK, Carter SD, Hayward R (2007) Effects of supervised exercise training on cardiopulmonary function and fatigue in breast cancer survivors during and after treatment. Cancer 110:918–925

    PubMed  Google Scholar 

  78. Schneider CM, Hsieh CC, Sprod LK, Carter SD, Hayward R (2007) Exercise training manages cardiopulmonary function and fatigue during and following cancer treatment in male cancer survivors. Integr Cancer Ther 6(3):235–241

    PubMed  Google Scholar 

  79. Schneider CM, Hsieh CC, Sprod LK, Carter SD, Hayward R (2007) Cancer treatment-induced alterations in muscular fitness and quality of life: The role of exercise training. Ann Oncol 18:1957–1962

    CAS  PubMed  Google Scholar 

  80. Balducci S, Iacobellis G, Parisi L, Di Biase N, Calandriello E, Leonetti F, Fallucca F (2006) Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Its Complicat 20:216–223

    Google Scholar 

  81. Richardson J, Sandman D, Vela S (2001) A focused exercise regimen improves clinical measures of balance in patients with peripheral neuropathy. Arch Phys Med Rehabil 82:205–209

    CAS  PubMed  Google Scholar 

  82. Tesfaye S, Harris ND, Wilson RM, Ward JD (1992) Exercise-induced conduction velocity increment: a marker of impaired peripheral nerve blood flow in diabetic neuropathy. Diabetologia 35:155–159

    CAS  PubMed  Google Scholar 

  83. Lindeman E, Leffers P, Spaans F, Drukker J, Reulen J, Kerckhoffs M, Koke A (1995) Strength training in patients with myotonic dystrophy and hereditary motor and sensory neuropathy: a randomized clinical trial. Arch Phys Med Rehabil 76(7):612–620

    CAS  PubMed  Google Scholar 

  84. Kilmer DD, McCroy MA, Wright NC, Aitkens SG, Bernauer EM (1994) The effect of a high resistance exercise program in slowly progressive neuromuscular disease. Arch Phys Med Rehabil 75(5):560–563

    CAS  PubMed  Google Scholar 

  85. Aitkens SG, McCrory MA, Kilmer DD, Bernauer EM (1993) Moderate resistance exercise program: its effect in slowly progressive neuromuscular disease. Arch Phys Med Rehabil 74(7):711–715

    CAS  PubMed  Google Scholar 

  86. Lindeman E, Leffers P, Reulen J, Spaans F, Drukker J (1998) Quadriceps strength and timed motor performances in myotonic dystrophy, Charcot-Marie-Tooth disease, and healthy subjects. Clin Rehabil 12(2):127–135

    CAS  PubMed  Google Scholar 

  87. Boulton AJM, Malik RA, Arezzo JC, Sosenko JM (2004) Diabetic somatic neuropathies. Diabetes Care 27:1458–1486

    PubMed  Google Scholar 

  88. Yong J, Loukianov E, Loukianova T, Jones LR, Periasamy M (1999) SERCA1a can functionally substitute for SERCA2a in the heart. Am J Physiol 276:H89–H97

    Google Scholar 

  89. Wu KD, Lee WS, Wey J, Bungard D, Lytton J (1995) Localization and quantification of endoplasmic reticulum Ca2+-ATPase isoform transcripts. Am J Physiol 269:C775–C784. Cell Physiol 38

    CAS  PubMed  Google Scholar 

  90. Kleuber KM, Feczko JD (1994) Ultrastructural, histochemical, and morphometric analysis of skeletal muscle in a murine model of type I diabetes. Anat Rec 239:18–34

    Google Scholar 

  91. Racz G, Szabo A, Ver A, Zador E (2009) The slow sarco/endoplasmic reticulum Ca2+-ATPase declines independently of slow myosin in soleus muscle of diabetic rats. Acta Biochim Pol 56:487–493

    CAS  PubMed  Google Scholar 

  92. Baselga J (2001) Herceptin® alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 61(suppl 2):14–21

    CAS  PubMed  Google Scholar 

  93. Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61:203–212

    CAS  PubMed  Google Scholar 

  94. Samantha A, LeVea CM, Dougall WC, Quian X, Greene MI (1994) Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation. Proc Natl Acad Sci USA 91:1711–1715

    Google Scholar 

  95. McGuire JF, Ruen S, Siegfreid E, Wright DE, Dobrowsky RT (2009) Caveolin-1 and altered neuregulin signaling contribute to the pathophysiological progression of diabetic peripheral neuropathy. Diabetes 58:2677–2686

    CAS  PubMed  Google Scholar 

  96. Yatime L, Buch-Pedersen MJ, Musgaard M et al (2009) P-type ATPases as drug targets: tools for medicine and science. Biophysica Acta 1787:207–220

    CAS  Google Scholar 

  97. Cook-Burns N (2001) Retrospective analysis of the safety of Herceptin® immunotherapy in metastatic breast cancer. Oncology 61(suppl 2):58–66

    Google Scholar 

  98. Feldman AM, Lorell BH, Reis SE (2000) Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity. Circulation 102:272–274

    CAS  PubMed  Google Scholar 

  99. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE (2003) The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 100(15):8933–8938

    CAS  PubMed  Google Scholar 

  100. Gustafsson T, Puntschart A, Kaijser L, Lansson E, Sundberg CJ (1999) Exercise-induced expression of angiogenesis-related transcription and growth factors in human skeletal muscle. Am J Physiol 276:H679–H685

    CAS  PubMed  Google Scholar 

  101. Fukai T, Siegfried MR, Ushio-Fukai M, Cheng Y, Kojda G, Harrison DG (2000) Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training. J Clin Invest 105:1631–1639

    CAS  PubMed  Google Scholar 

  102. Wisloff U, Loennechen JP, Falck G, Veisvag V, Currie S, Smith G, Ellingsen O (2001) Increased contractility and calcium sensitivity in cardiac myocytes isolated from endurance trained rats. Cardiovasc Res 50:495–508

    CAS  PubMed  Google Scholar 

  103. Tate CA, Taffet GE, Hudson EK, Blaylock SL, McBride RP, Michael LH (1990) Enhanced calcium uptake of cardiac sarcoplasmic reticulum in exercise-trained old rats. Am J Physiol 258:H431–H435. Heart Circ Physiol 27

    CAS  PubMed  Google Scholar 

  104. Tate CA, Helgason T, Hyek MF, McBride RP, Chen M, Richardson MA, Taffet GE (1996) SERCA2a and mitochondrial cytochrome oxidase expression are increased in hearts of exercise-trained old rats. Am J Physiol 271:H68–H72. Heart Circ Physiol 40

    CAS  PubMed  Google Scholar 

  105. Wonders KY, Hydock DS, Greufe S, Schneider CM, Hayward R (2009) Endurance training preserves cardiac function in rats receiving doxorubicin and the HER2-inhibitor GW2974. Cancer Chemother Pharmacol 64(6):1105–1113

    CAS  PubMed  Google Scholar 

  106. Obrosova IG, Drel VR, Pacher P et al (2005) Oxidative-nitrosative stress and poly(ADP-Ribose) polymerase PPARP) activation in experimental diabetic neuropathy: the relation is revisited. Diabetes 54:3435–3441

    CAS  PubMed  Google Scholar 

  107. Obrosova IG, Drel VR, Oltman CL et al (2007) Rose of nitrosative stress in early neuropathy and vascular dysfunction in streptozotcin-diabetic rats. Am J Physiol Endocrinol Metab 293:E1645–E1655

    CAS  PubMed  Google Scholar 

  108. Koltyn KF, Wertz AL, Gardiner RL et al (1996) Perception of pain following aerobic exercise. Med Sci Sports Exerc 28:1418–1421

    CAS  PubMed  Google Scholar 

  109. Gurevich M, Kohn PM, Davis C (1994) Exercise-induced analgesia and the role of reactivity in pain sensitivity. J Sports Sci 12:549–559

    CAS  PubMed  Google Scholar 

  110. Sternberg WF, Bokat C, Kass L et al (2001) Sex-dependent components of the analgesia produced by athletic competition. Pain 94:65–74

    Google Scholar 

  111. Sternberg WF, Bailin D, Grant M et al (1998) Competition alters the perception of noxious stimuli in male and female athletes. Pain 76:231–238

    CAS  PubMed  Google Scholar 

  112. Haier RJ, Quaid K, Mills JSC (1981) Naloxone alters pain perception after jogging. Psychiatry Res 5:231–232

    CAS  PubMed  Google Scholar 

  113. Koltyn KF, Arbogast RW (1998) Perception of pain after resistance exercise. Br J Sports Med 32:20–24

    CAS  PubMed  Google Scholar 

  114. Carter GT, Kikuchi N, Abresch RT, Walsh SA, Horasek S, Fowler WM (1994) Effects of exhaustive concentric and eccentric exercise on murine skeletal muscle. Arch Phys Med Rehabil 75:555–559

    CAS  PubMed  Google Scholar 

  115. Carter GT, Abresch RT, Fowler WM (2002) Adaptations to exercise training and contraction-induced muscle injury in animal models of neuromuscular disease. Am J Phys Med Rehabil 81(suppl):S151–S161

    PubMed  Google Scholar 

  116. Breslin E, Booth J, Lord B et al (1993) Respiratory responses to unsupported arm exercise (UAE) in Charcot Marie Tooth (CMT) [abstract]. American Thoracic Society. Am Rev Respir Dis 147:A532

    Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Health, Physical Education and Recreation, Wright State University, 316 Nutter Center, 3640 Colonel Glenn Hwy, Dayton, OH, 45435, USA

    Karen Y. Wonders

  2. College of Nursing, University of Cincinnati, 3110 Vine Street, Cincinnati, OH, 45221, USA

    Beverly S. Reigle

  3. Department of Health Sciences, Gettysburg College, Gettysburg, PA, 17325, USA

    Daniel G. Drury

Authors
  1. Karen Y. Wonders
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Beverly S. Reigle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel G. Drury
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karen Y. Wonders.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wonders, K.Y., Reigle, B.S. & Drury, D.G. Treatment strategies for chemotherapy-induced peripheral neuropathy: potential role of exercise. Oncol Rev 4, 117–125 (2010). https://doi.org/10.1007/s12156-010-0044-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12156-010-0044-1

Keywords

Search

Navigation